Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Initial U.S. data shows the RSV vaccine is highly effective in older adults, significantly cutting severe illness and hospitalization rates. Recent findings from a multi-state study reveal that the ...

US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...

It’s also a celebration of the arrival of Jesus. Christmas is a time for Christians to praise God’s love for the world through the birth of His Son: Jesus. The Bible tells of His birth hundreds of ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

These data show the vaccine’s potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV. In the US alone, the number of adults aged 18-49 with ...

The NHS vaccination programme to protect vulnerable people in the South East from a potential ‘tripledemic’ of Covid-19, flu, and respiratory syncytial virus (RSV) is off to a strong start. Over 1 ...

But there’s another virus out there that can also cause these symptoms: It’s called respiratory syncytial virus (RSV), and even if you’ve never heard of it before, there’s a very good ...

As winter's chill sweeps across the nation, health experts have urged Brits to brace for a 'tripledemic', with a likely uptick in cases of covid, flu, and RSV. Brits are urged to get vaccinated ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

The U.S. is entering the second RSV season in which vaccines for the virus are available for older adults. Yet, despite three options on the market from Pfizer, GSK and Moderna, uptake has been slow ...